Ann Marie Egloff

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma
    Ann Marie Egloff
    Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Head Neck 35:270-9. 2013
  2. ncbi Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy
    Ann Marie Egloff
    Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 18:5188-95. 2012
  3. ncbi Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study
    Ann Marie Egloff
    Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Respir Res 13:9. 2012
  4. ncbi Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma
    Ann Marie Egloff
    Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
    Clin Cancer Res 15:6529-40. 2009
  5. ncbi Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms
    Stephen Y Lai
    Departments of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    J Clin Oncol 27:1235-42. 2009
  6. ncbi Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Invest New Drugs 30:1575-84. 2012
  7. ncbi HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer
    Lynn M Knowles
    Departments of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 15:3740-50. 2009
  8. ncbi Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma
    Sarah Wheeler
    Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 18:2278-89. 2012
  9. ncbi SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells
    Michael S Leibowitz
    Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA
    Clin Cancer Res 19:798-808. 2013
  10. ncbi Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma
    Priya Koppikar
    Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 14:4284-91. 2008

Collaborators

Detail Information

Publications19

  1. ncbi Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma
    Ann Marie Egloff
    Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Head Neck 35:270-9. 2013
    ....
  2. ncbi Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy
    Ann Marie Egloff
    Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 18:5188-95. 2012
    ..Defining the status and consequences of altered Notch signaling will be important for selection of appropriate treatment...
  3. ncbi Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study
    Ann Marie Egloff
    Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Respir Res 13:9. 2012
    ..We sought to define the contribution of GRPR expression in bronchial epithelia to lung cancer risk in a larger case-control study where adjustments could be made for tobacco exposure and sex...
  4. ncbi Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma
    Ann Marie Egloff
    Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
    Clin Cancer Res 15:6529-40. 2009
    ....
  5. ncbi Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms
    Stephen Y Lai
    Departments of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    J Clin Oncol 27:1235-42. 2009
    ..A phase I clinical trial was conducted to evaluate the safety and biologic effects of EGFR AS...
  6. ncbi Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Invest New Drugs 30:1575-84. 2012
    ..We evaluated the combination of dasatinib, an inhibitor of SFK and other kinases, and cetuximab, an anti-EGFR monoclonal antibody...
  7. ncbi HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer
    Lynn M Knowles
    Departments of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 15:3740-50. 2009
    ....
  8. ncbi Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma
    Sarah Wheeler
    Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 18:2278-89. 2012
    ..Tumor (n = 50) EGFR and EGFRvIII mRNA levels were quantified using real-time PCR...
  9. ncbi SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells
    Michael S Leibowitz
    Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA
    Clin Cancer Res 19:798-808. 2013
    ..We investigated whether an overexpressed phosphatase was responsible for basal suppression of pSTAT1 and subsequent APM component-mediated immune escape in HNC cells...
  10. ncbi Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma
    Priya Koppikar
    Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 14:4284-91. 2008
    ..This study was undertaken to elucidate the role of c-Src in the growth and invasion of HNSCC and to determine the effects of combined targeting of EGFR and Src kinases in HNSCC cell lines...
  11. ncbi An informatics supported web-based data annotation and query tool to expedite translational research for head and neck malignancies
    Waqas Amin
    Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA
    BMC Cancer 9:396. 2009
    ....
  12. ncbi TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression
    Umamaheswar Duvvuri
    Department of Otolaryngology, University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine and Magee Women s Research Institute, Pittsburgh, Pennsylvania 15213, USA
    Cancer Res 72:3270-81. 2012
    ..The development of small-molecule inhibitors against TMEM16A may be clinically relevant for treatment of human cancers, including SCCHN...
  13. ncbi Anatomic variants on computed tomography in congenital aural atresia
    Kavita Dedhia
    Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Otolaryngol Head Neck Surg 147:323-8. 2012
    ..Anatomic variants included inferiorly displaced/obstructing tegmen mastoideum, malleus-incus complex (MIC) directly lateral to stapes, facial nerve obstruction of oval window (OW) or middle ear, and incudostapedial joint (ISJ) angle...
  14. ncbi Chemokine receptor 7 (CCR7) gene expression is regulated by NF-κB and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN)
    Yvonne K Mburu
    Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
    J Biol Chem 287:3581-90. 2012
    ..As such, CCR7, NF-κB, and AP1 could be potentially useful therapeutic targets in controlling the progression and metastasis of SCCHN tumors...
  15. ncbi Response to combined molecular targeting: defining the role of P-STAT3
    Ann Marie Egloff
    Department of Otolaryngology and Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 17:393-5. 2011
    ..Tumor P-STAT3 levels may be an important indicator of EGFR- and SKF-targeted antitumor treatment efficacy...
  16. ncbi Histological assessment of cervical lymph node identifies patients with head and neck squamous cell carcinoma (HNSCC): who would benefit from chemoradiation after surgery?
    Xiao Chloe Wan
    School of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Laryngoscope 122:2712-22. 2012
    ..In this study, we assessed cervical lymph node histological characteristics to detect prognostic and predictive value differences to help guide therapeutic decision making...
  17. ncbi Congenital cholesteatoma: predictors for residual disease and hearing outcomes
    Amanda L Stapleton
    Department of Pediatric Otolaryngology, Children s Hospital of Pittsburgh of the University of Pittsburgh Medical Center, Pittsburgh, PA 15224, USA
    Arch Otolaryngol Head Neck Surg 138:280-5. 2012
    ..To determine predictive factors for residual disease and hearing outcomes of surgery for congenital cholesteatoma (CC)...
  18. ncbi Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer
    Ann Marie Egloff
    Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Semin Oncol 35:286-97. 2008
    ..Here, we discuss agents targeting ErbB and Src family kinases in clinical development, provide an overview of completed and ongoing clinical trials, and outline a molecular rationale for combining ErbB- and Src-targeted therapeutics...
  19. ncbi Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer
    Ann Marie Egloff
    University of Pittsburgh School of Medicine, E1040 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Ann N Y Acad Sci 1062:29-40. 2005
    ....